Peptide vaccines and pembrolizumab for treating breast cancer
AssigneeOncopep, Inc.
InventorsDoris Peterkin, Marc A. Cohen
Life of this patent
Estimating the term…
Abstract
The disclosure features, inter alia, combination therapies comprising pembrolizumab and one or more immunogenic XBP1-, CD138-, and CS1-derived peptides. The therapies herein can be used, e.g., for inducing an immune response in a subject having a cancer, and treating a cancer such as breast cancer, e.g., triple negative breast cancer.
Claims26
A method of treating breast cancer comprising administering to a subject:
- (i) pembrolizumab;
- and
- (ii) one or more of:
- a non-spliced XBP1 peptide, a spliced XBP1 peptide, a CD138 peptide and a CS-1 peptide;
- wherein the subject has, or is at risk of developing, breast cancer.
Pembrolizumab, in combination with:
- one or more of:
- a non-spliced XBP1 peptide, a spliced XBP1 peptide, a CD138 peptide and a CS-1 peptide;
- for use in treating breast cancer.
A method for inducing an immune response in a subject, the method comprising delivering to a subject:
- (i) pembrolizumab;
- and
- (ii) one or more of:
- a non-spliced XBP1 peptide, a spliced XBP1 peptide, a CD138 peptide and a CS-1 peptide.
Pembrolizumab, in combination with:
- one or more of:
- a non-spliced XBP1 peptide, a spliced XBP1 peptide, a CD138 peptide and a CS-1 peptide;
- for use in inducing an immune response in a subject.
6-8. (canceled)
10-18. (canceled)
(canceled)
(canceled)
31-33. (canceled)
(canceled)
Dependencies are inferred from the claim text.